Laurus Labs Share Price Analyzed

Key Points

• Stock surged 1% to ₹1,095, showing strong growth.
• Laurus Labs grew 33% in revenue year-on-year (Y-o-Y).
• EBITDA margins jumped significantly due to better product mix.
• Over 110 active projects, including healthcare & crop science.
• Expansion plans: new fermentation facility and increased capacity.
• Analysts predict strong growth (30% CAGR) over the next few years.

The Laurus Labs share price jumped up significantly on Tuesday, reaching a new high of ₹1,095. This means the stock went up by 1% in just one day! This increase was because investors are excited about how well the company is doing, especially in making medicines for other companies.

Over the past five weeks, Laurus Labs’ stock has also gone up by 12%. That means the stock price has been steadily climbing. This is good news for people who own the stock, as it shows the company is doing well.

During the last year (2025), Laurus Labs has done incredibly well. It’s grown by a huge 82%, which is much more than the rest of the stock market, which only went up 8%. This makes Laurus Labs one of the best-performing companies in India.

To understand why Laurus Labs is doing so well, let’s look at what’s happening with the company. They are making more medicines than ever before. They’re selling these medicines to other companies, which is a big part of their business. This is called being a “Contract Development and Manufacturing Organisation” or CDMO.

The company is making a lot more money because they’re selling more medicines and because they’re getting better at making them. They’re also investing in new equipment and building new factories. This will help them make even more medicines in the future.

Laurus Labs has a plan to grow even more. They want to build a big factory in Vizag, which will allow them to make a lot more medicines. They’re also working on new projects and adding more medicines to their list.

Experts at Motilal Oswal Financial Services think this CDMO business will grow by 30% every year for the next few years. They believe Laurus Labs will make around ₹3,000 crore in sales. They’ve even raised their predictions for how much money the company will make in the future, because of improved medicines for fighting HIV and because they’re getting more business making medicines for other companies.

Laurus Labs is spending a lot of money to grow – about ₹1,000 crore this year and even more in the years to come. This shows they’re serious about becoming a huge player in the pharmaceutical industry. Analysts target a price of ₹1,110, based on these growth expectations.

The company is also expanding its research labs, which will help them create even more new medicines. They’ve been given a large piece of land to build a big, modern factory, which is a really good sign for the future.

“The future looks bright for Laurus Labs as they continue to innovate and expand their capabilities, positioning them as a key player in the global pharmaceutical market.”